Using dose-response characteristics of therapeutic agents for treatment decisions in type 2 diabetes

被引：14

作者：

Garber, AJ ^{[1
]}

机构：

[1] Methodist Hosp, Baylor Coll Med, Houston, TX 77030 USA

来源：

关键词：

dose-response; metformin; sulphonylureas; troglitazone;

D O I：

10.1046/j.1463-1326.2000.00054.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：139 / 147

页数：9

共 58 条

[1] *AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS36
[2] American Diabetes Association, 1998, DIABETES CARE, pS23
[3] [Anonymous], 1995, Br. Med. J, DOI DOI 10.1136/BMJ.310.6972.83
[4] [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[5] HYPOGLYCEMIC, ANTIHYPERGLYCEMIC AND ANTIDIABETIC DRUGS
BAILEY, CJ
[J]. DIABETIC MEDICINE, 1992, 9 (05) : 482 - 483
[6] *BAY CORP, 1999, PREC AC TABL PACK IN
[7] Insulin resistance: Current concepts
Bloomgarden, ZT
[J]. CLINICAL THERAPEUTICS, 1998, 20 (02) : 216 - 231
[8] *BRIST MEY SQUIBB, 1998, GLUC METF HYDR PACK
[9] Lactic acidosis rates in type 2 diabetes
Brown, JB
Pedula, K
Barzilay, J
Herson, MK
Latare, P
[J]. DIABETES CARE, 1998, 21 (10) : 1659 - 1663
[10] CONIFF RF, 1994, ARCH INTERN MED, V154, P2442